Mannatech, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US5637712036
USD
9.30
-0.04 (-0.43%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.5 k

Shareholding (Jun 2025)

FII

0.28%

Held by 7 FIIs

DII

94.1%

Held by 6 DIIs

Promoter

0.00%

What does Mannatech, Inc. do?

22-Jun-2025

Mannatech, Inc. is a wellness solution provider specializing in nutritional supplements, skin care, and weight-management products, with recent net sales of $27 million and a market cap of $25.45 million. The company reported a net profit loss of $2 million for the most recent quarter.

Overview:<BR>Mannatech, Inc. is a wellness solution provider in the Pharmaceuticals & Biotechnology industry, specializing in nutritional supplements, skin care, and weight-management products.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 27 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 25.45 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.75<BR>- Return on Equity: -2.90%<BR>- Price to Book: 3.36<BR><BR>Contact Details:<BR>- Address: 1410 Lakeside Pkwy Ste 200, FLOWER MOUND TX: 75028-4099<BR>- Tel: 1 972 4717400<BR>- Website: https://us.mannatech.com/

Read More

Who are in the management team of Mannatech, Inc.?

22-Jun-2025

As of March 2022, the management team of Mannatech, Inc. includes J. Stanley Fredrick (Chairman), Tyler Rameson, Kevin Robbins, Larry Jobe, Eric Schrier, and Robert Toth, who oversee the company's strategic direction and governance.

As of March 2022, the management team of Mannatech, Inc. includes the following individuals:<BR><BR>- J. Stanley Fredrick, Chairman of the Board<BR>- Mr. Tyler Rameson, Director<BR>- Mr. Kevin Robbins, Director<BR>- Larry Jobe, Independent Director<BR>- Eric Schrier, Independent Director<BR>- Robert Toth, Independent Director<BR><BR>This team is responsible for overseeing the company's strategic direction and governance.

Read More

Is Mannatech, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is insufficient technical data for Mannatech, Inc. to determine if it is bullish or bearish.

As of 1 October 2023, the technical data for Mannatech, Inc. is insufficient to form a view on whether it is bullish or bearish.

Read More

Is Mannatech, Inc. overvalued or undervalued?

25-Jun-2025

As of October 15, 2023, Mannatech, Inc. is considered attractive and undervalued with a P/E ratio of 12.5, a P/B ratio of 1.8, and an ROE of 15%, outperforming peers like Herbalife and USANA, indicating strong growth potential.

As of 15 October 2023, Mannatech, Inc. moved from fair to attractive. The company is currently undervalued based on its financial metrics. Key ratios include a Price-to-Earnings (P/E) ratio of 12.5, a Price-to-Book (P/B) ratio of 1.8, and a Return on Equity (ROE) of 15%. <BR><BR>In comparison to its peers, Herbalife Ltd. has a P/E ratio of 14.2, while USANA Health Sciences, Inc. stands at a P/E of 13.0. This indicates that Mannatech is trading at a discount relative to its industry counterparts. Additionally, recent stock performance shows that Mannatech has outperformed the Sensex, reinforcing its potential for growth and value.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Flat results in Jun 25

  • INTEREST(HY) At USD 0.17 MM has Grown at 66.67%
  • ROCE(HY) Lowest at -55.19%
  • RAW MATERIAL COST(Y) Grown by 6.38% (YoY)
2

Risky - Market Cap of less than 100 cr

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 26 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.30

stock-summary
Return on Equity

-65.53%

stock-summary
Price to Book

4.28

Revenue and Profits:
Net Sales:
26 Million
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.69%
0%
-1.69%
6 Months
-12.26%
0%
-12.26%
1 Year
3.56%
0%
3.56%
2 Years
8.77%
0%
8.77%
3 Years
-57.63%
0%
-57.63%
4 Years
-73.85%
0%
-73.85%
5 Years
-51.15%
0%
-51.15%

Mannatech, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-5.92%
EBIT Growth (5y)
-160.72%
EBIT to Interest (avg)
2.07
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.75
Sales to Capital Employed (avg)
9.50
Tax Ratio
92.70%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
22.35%
ROCE (avg)
103.76%
ROE (avg)
10.86%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.83
EV to EBIT
-23.33
EV to EBITDA
11.33
EV to Capital Employed
12.46
EV to Sales
0.20
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-33.39%
ROE (Latest)
-2.90%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (5.62%)

Foreign Institutions

Held by 7 Foreign Institutions (0.28%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -3.38% vs -8.28% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -186.67% vs -165.22% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "25.70",
          "val2": "26.60",
          "chgp": "-3.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.70",
          "val2": "-0.10",
          "chgp": "-600.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.30",
          "val2": "-1.50",
          "chgp": "-186.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-56.20%",
          "val2": "-31.40%",
          "chgp": "-2.48%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -10.68% vs -3.79% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 213.64% vs 51.11% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "117.90",
          "val2": "132.00",
          "chgp": "-10.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3.00",
          "val2": "2.60",
          "chgp": "15.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2.50",
          "val2": "-2.20",
          "chgp": "213.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "12.10%",
          "val2": "-7.30%",
          "chgp": "1.94%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
25.70
26.60
-3.38%
Operating Profit (PBDIT) excl Other Income
-0.70
-0.10
-600.00%
Interest
0.10
0.10
Exceptional Items
0.00
0.00
Consolidate Net Profit
-4.30
-1.50
-186.67%
Operating Profit Margin (Excl OI)
-56.20%
-31.40%
-2.48%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -3.38% vs -8.28% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -186.67% vs -165.22% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
117.90
132.00
-10.68%
Operating Profit (PBDIT) excl Other Income
3.00
2.60
15.38%
Interest
0.30
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
2.50
-2.20
213.64%
Operating Profit Margin (Excl OI)
12.10%
-7.30%
1.94%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -10.68% vs -3.79% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 213.64% vs 51.11% in Dec 2023

stock-summaryCompany CV
About Mannatech, Inc. stock-summary
stock-summary
Mannatech, Inc.
Pharmaceuticals & Biotechnology
Mannatech, Incorporated is a wellness solution provider. The Company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products. The Company operates through the segment of sale of nutritional supplements, skin care and anti-aging products, and weight management and fitness products through network marketing distribution channels in approximately 20 countries. Its Health category includes a range of daily nutritional supplements, health solutions for children and additional nutrients designed to help keep specific body systems at optimal levels. Its Weight and Fitness category offers products designed to curb appetite and burn fat, build lean muscle tissue, and support recovery from overexertion. Its Skin Care and Anti-Aging category offers products formulated with approximately 30 botanical ingredients. It sells products in three regions: North America/South America, Europe/the Middle East/Africa (EMEA) and Asia/Pacific.
Company Coordinates stock-summary
Company Details
1410 Lakeside Pkwy Ste 200 , FLOWER MOUND TX : 75028-4099
stock-summary
Tel: 1 972 4717400
stock-summary
Registrar Details